

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
John Graham	Specialist Committee Member	Direct – financial	Invited presentation on the use of tamoxifen for the prevention of breast cancer to Medicines and Healthcare products Regulatory Agency. Honorarium of £200 plus travel expenses.	28/09/2017			Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – financial	Invited lecture at the American Society of Clinical Oncology Annual Meeting in Chicago. Honorarium of \$500 plus conference fee, travel and accommodation expenses.	03/06/2017		06/06/2017	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – financial	ASCO Genito-Urinary Cancer Conference, Orlando, Florida. Conference fee, travel and accommodation paid by Bayer Health Care.	16/02/2017		18/02/2017	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – financial	Private practice in the non-surgical management of breast and urological cancer (external beam radiotherapy and chemotherapy).	July 1992		ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – financial	Attended a trial investigator meeting in Berlin for a planned bladder cancer trial with rogaratinib. Accommodation and	June 2018		June 2018	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
John Graham (continued)	Specialist Committee Member		travel expenses paid by Bayer Pharmaceuticals				
		Direct – non-financial	Principal investigator for the following ongoing commercially funded clinical trials in prostate cancer: i) Radium-223 funded by Bayer Health Care ii) Rucaparib funded by Clovis Oncology	31/07/2014 01/02/2018		Ongoing Ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – non-financial	Principal or co-investigator for the following ongoing non-commercially funded clinical trials in prostate cancer: i) Stampede ii) The UK Genetic Prostate Cancer Study iii) Prompts iv) TOPARP v) CTC Stop	2005 2006 June 2013 Aug 2017 Jan 2018		Ongoing Ongoing Ongoing Ongoing Ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – non-financial	Member of the trial management group for the RT01 trial of external beam radiotherapy for prostate cancer.	2004		Ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 13/6/2018
		Direct – non-financial	Member of the trial management group for the CHHIP trial of	July 2007		Ongoing	Declare and participate.
John Graham (continued)							

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
	Specialist Committee Member		external beam radiotherapy for prostate cancer.				Acting Programme Director – Devices and Diagnostics 13/6/2018
Britta Stordal	Specialist Committee Member	None	None	N/A	N/A	N/A	No action needed
Ursula Van Mann	Specialist Committee Member	None	None	N/A	N/A	N/A	No action needed
Deirdre Ryan	Specialist Committee Member	None	None	N/A	N/A	N/A	No action needed
Linda Pepper	Specialist Committee Member	None	None	N/A	N/A	N/A	No action needed
Maria Bramley	Specialist Committee Member	None	None	N/A	N/A	N/A	No action needed
Andrew Wardley	Specialist Committee Member	Direct - financial	Consultancy fee from Genomic Health UK for advisory board	2015		2015	Declare and participate. Acting Programme Director – Devices and Diagnostics 11/6/2018

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Mark Kroese	Chair – Diagnostics Advisory Committee	None	N/A	N/A	N/A	N/A	No action needed
Alexandria Moseley	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Anthony Wierzbicki	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Chris Hyde	Standing Committee member	Indirect financial	I work for University which is an evidence contractor for NICE (PenTAG at University of Exeter). The report for this guidance was not produced by our group	4/2016		3/2021	Declare and participate. Acting Programme Director – Devices and Diagnostics 11/6/2018
Dermot Neely	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Enitan Carrol	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Jim Gray	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
John Bagshaw	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
John Hitchman	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Liz Adair	Standing Committee member	Indirect	Roche diagnostics supply products and equipment to Viapath Services LLP. I am the Director of Viapath Group LLP.	June 2014	May 2014	Present	Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018
Mark Sculpher	Standing Committee member	Direct	Consultancy fee from Roche Diagnostics. This work has nothing to do with these products or breast cancer.	2017-18		Ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018
Matt Stevenson	Standing Committee member	Direct Non-financial professional and personal interests	I am the director of SchARR-TAG who have been allocated to undertake the DAR.	Start of the DAR		End of the DAR	Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018
Michael Messenger	Standing Committee member	Direct non-financial	I am a co-investigator on a recent Myriad Genetics funded health economics evaluation at the University of Leeds, evaluating the impact of an unrelated test, Prolaris for prostate cancer prognosis. As part of this, Myriad Genetics paid for my lunch (<£20) on 3rd October 2017 to discuss the Prolaris project	31/07/2014		Ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Michael Messenger (continued)	Standing Committee member	Indirect – Non-Financial	Colleagues within the NIHR MIC in Leeds, for which I am the Deputy Director, are co-investigators on the OPTIMA trial	06/2014		Ongoing	Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018
		Direct – Non-Financial	Myriad Genetics approached me about a potential future evaluation of EndoPredict. I said I would not discuss this with them until the revision of DG10 is complete.	02/03/2014		02/03/2014	
		Indirect - Financial	Myriad Genetics, Roche Diagnostics and Genomic Health sponsored the NIHR Leeds In Vitro Diagnostic Launch event	07/03/2018		07/03/2018	
Nick Summerton	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Owen Driskell	Standing Committee member	Indirect personal	My wife works as a Health and Safety professional at AstraZeneca's Maccelsfield site				Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018
Patrick McGinley	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed

Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: 19 December 2018

Topic: Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Shelley Rahman Haley	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Simon Fleming	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed
Simon Richards	Standing Committee member	Direct financial	Employed as RA Vice President by Abbott who are a direct competitor to Roche Diagnostics.	October 2017			Declare and participate. Acting Programme Director – Devices and Diagnostics 6/6/2018
Steve Halligan	Standing Committee member	None	N/A	N/A	N/A	N/A	No action needed